Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,512 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Ishizuchi K, Tokuyasu D, Handa H, Yasuda M, Kawaguchi N, Kimura T, Suzuki Y, Sugimoto T, Minami N, Takahashi MP, Murai H, Utsugisawa K. Suzuki S, et al. Among authors: sugimoto t. Neurol Clin Pract. 2024 Jun;14(3):e200276. doi: 10.1212/CPJ.0000000000200276. Epub 2024 Mar 25. Neurol Clin Pract. 2024. PMID: 38544885 Free PMC article.
Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Howard JF Jr, et al. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Lancet Neurol. 2021. PMID: 34146511 Clinical Trial.
Impact of Early Treatment with Intravenous High-Dose Methylprednisolone for Ocular Myasthenia Gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: sugimoto t. Neurotherapeutics. 2023 Mar;20(2):518-523. doi: 10.1007/s13311-022-01335-3. Epub 2023 Jan 6. Neurotherapeutics. 2023. PMID: 36607596 Free PMC article.
Effectiveness of early cycles of fast-acting treatment in generalised myasthenia gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: sugimoto t. J Neurol Neurosurg Psychiatry. 2023 Jun;94(6):467-473. doi: 10.1136/jnnp-2022-330519. Epub 2023 Jan 24. J Neurol Neurosurg Psychiatry. 2023. PMID: 36693723
Clinical features and outcomes of patients with muscle-specific kinase antibody-positive myasthenia gravis in Japan.
Yasuda M, Uzawa A, Kuwabara S, Suzuki S, Akamine H, Onishi Y, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Yasuda M, et al. Among authors: sugimoto t. J Neuroimmunol. 2023 Dec 15;385:578241. doi: 10.1016/j.jneuroim.2023.578241. Epub 2023 Nov 7. J Neuroimmunol. 2023. PMID: 37952282
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Sugimoto T, Ishizuchi K, Oyama M, Yasuda M, Akamine H, Onishi Y, Suzuki Y, Kawaguchi N, Minami N, Kimura T, Takahashi MP, Murai H, Utsugisawa K. Tokuyasu D, et al. Among authors: sugimoto t. Ann Clin Transl Neurol. 2024 May;11(5):1338-1346. doi: 10.1002/acn3.52051. Epub 2024 Apr 4. Ann Clin Transl Neurol. 2024. PMID: 38572524 Free PMC article.
Taste disorders and alopecia in myasthenia gravis.
Uzawa A, Suzuki S, Kuwabara S, Akamine H, Onishi Y, Yasuda M, Ozawa Y, Kawaguchi N, Kubota T, Takahashi MP, Suzuki Y, Watanabe G, Kimura T, Sugimoto T, Samukawa M, Minami N, Masuda M, Konno S, Nagane Y, Utsugisawa K. Uzawa A, et al. Among authors: sugimoto t. BMC Neurol. 2024 Apr 25;24(1):139. doi: 10.1186/s12883-024-03644-w. BMC Neurol. 2024. PMID: 38664714 Free PMC article.
[The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Sugimoto T, Yamawaki T, Naito H, Ohno N, Giga M, Kono T, Ochi K, Kohriyama T, Nomura E, Maruyama H. Sugimoto T, et al. Rinsho Shinkeigaku. 2022 Dec 17;62(12):915-921. doi: 10.5692/clinicalneurol.cn-001790. Epub 2022 Nov 29. Rinsho Shinkeigaku. 2022. PMID: 36450489 Japanese.
Ultrasonographic nerve enlargement of the median and ulnar nerves and the cervical nerve roots in patients with demyelinating Charcot-Marie-Tooth disease: distinction from patients with chronic inflammatory demyelinating polyneuropathy.
Sugimoto T, Ochi K, Hosomi N, Takahashi T, Ueno H, Nakamura T, Nagano Y, Maruyama H, Kohriyama T, Matsumoto M. Sugimoto T, et al. J Neurol. 2013 Oct;260(10):2580-7. doi: 10.1007/s00415-013-7021-0. Epub 2013 Jul 3. J Neurol. 2013. PMID: 23821028
3,512 results